New Initiative Aims to Crack the Long COVID Diagnostic Code

MEDFORD, Mass. – March 24, 2026 – A major new initiative is launching to tackle one of the most significant obstacles in the fight against Long COVID: the absence of reliable diagnostic tests. The PolyBio Research Foundation today announced the VIPER program, a large-scale effort to validate clinical tools that can definitively identify the biological drivers of the debilitating condition. With an initial deployment of $1.35 million to the University of California San Francisco (UCSF), the program marks a pivotal shift towards a precision-medicine approach for the millions still suffering from the aftermath of a COVID-19 infection.

VIPER, which stands for Viral Immunopathogenesis and Persistence Repeat Donor Cohort, is the first phase of a broader strategy called the Long COVID Cure Initiative (LCCI). This multi-step plan is designed to systematically dismantle the barriers that have prevented scientific discoveries from becoming effective, accessible treatments.

The Diagnostic Dilemma

Years after the pandemic began, Long COVID remains a frustrating enigma for patients and clinicians alike. The condition, which can affect nearly every organ system, is currently diagnosed based on a constellation of patient-reported symptoms, ranging from debilitating fatigue and brain fog to cardiovascular and neurological issues. This reliance on subjective criteria has created a diagnostic crisis.

Major research efforts, including the NIH's $1.15 billion RECOVER Initiative, have confirmed that routine blood tests are often normal in Long COVID patients and cannot reliably distinguish them from individuals who have fully recovered. This lack of objective biological markers, or biomarkers, has created a critical bottleneck. Without a definitive test, patient populations in clinical trials are incredibly diverse, making it nearly impossible to determine if a potential therapy is effective. Promising treatments may be dismissed as failures simply because they were tested on the wrong group of patients.

This diagnostic uncertainty leaves millions in a state of limbo, often struggling to have their condition recognized while navigating a healthcare system unequipped to measure, let alone treat, their illness. VIPER is designed to solve this exact problem.

The VIPER Strike: A New Diagnostic Arsenal

The VIPER program will conduct rigorous, head-to-head evaluations of the most promising diagnostic tests emerging from research laboratories. Many of these tools exist only as academic experiments—unstandardized and unavailable for clinical use. VIPER's goal is to put them through their paces to determine which ones most accurately detect the core mechanisms believed to drive Long COVID.

Key among these mechanisms is the persistence of the SARS-CoV-2 virus or its components in bodily tissues long after the initial infection has cleared. Research from UCSF's own LIINC study, which VIPER builds upon, has provided strong evidence for this phenomenon. The study has identified lingering viral fragments in tissues and documented signs of ongoing immune system activation, neuroinflammation, and even reductions in key neurotransmitters like serotonin in Long COVID patients.

VIPER will validate tests designed to detect this viral persistence, as well as those that measure related immune dysfunction and clotting abnormalities. The program's design is modeled on the landmark work that transformed HIV from a complex, untreatable syndrome into a manageable chronic condition through the development of a single, transformative diagnostic test.

"Having witnessed how a single test can transform a complex disease like HIV, I am fully committed to doing my part to develop tests for Long COVID," said Dr. Steven Deeks, a Professor of Medicine at UCSF and a senior investigator for the new program. "Validated diagnostics will allow us to run smarter, more targeted trials - and ultimately deliver effective treatments to patients faster."

From Lab to Clinic: A Blueprint for a Cure

VIPER is the foundational first step in PolyBio's ambitious, four-part Long COVID Cure Initiative. The LCCI roadmap is designed to create a direct and accelerated pipeline from scientific discovery to patient care.

Following the validation of tests in the VIPER phase, the second step will be to catalyze their commercialization, ensuring they become widely available as clinical-grade tools. The third step will leverage these new diagnostics to mobilize smarter clinical trials. Instead of enrolling a broad, undefined Long COVID population, researchers will be able to stratify patients based on their specific underlying biology—for instance, grouping patients with confirmed viral persistence to test antiviral drugs.

The final phase aims to scale clinical adoption, integrating the validated diagnostics and proven treatments into standard medical practice. This comprehensive strategy demonstrates a clear understanding that developing a test is not the end goal, but rather the essential key needed to unlock the entire pathway to effective care.

Philanthropy Fueled by Personal Stakes

The initiative is being powered by a donor coalition that includes the Pagliuca family and healthcare philanthropists Greg and Mindy White, each of whom has family members personally affected by Long COVID. Their involvement underscores a growing movement where private funding, driven by personal urgency, is stepping in to accelerate progress on pressing medical challenges.

"Long COVID represents one of the most urgent unmet medical challenges of our time," said Steve Pagliuca, Founder & CEO of PagsGroup. "Scientific insights are advancing, but they are not yet reaching patients. The Long COVID Cure Initiative is changing that by systematically accelerating the path from discovery to real-world treatments."

This sentiment was echoed by Greg White, who emphasized the program's strategic importance.

"The VIPER program builds the diagnostic foundation required to translate discovery into care, enabling smarter clinical trials and a coordinated path to treatments that actually match the biology of the disease," said White. "This is the kind of rigorous, integrated infrastructure needed to move an entire Long COVID field forward."

By focusing on the unglamorous but essential work of diagnostic validation, the VIPER program and the broader LCCI represent a profound investment in clarity. For the millions navigating the uncertainty of Long COVID, this new, methodical approach provides a tangible and structured source of hope, promising to build the foundation upon which a cure can finally be constructed.